Thursday, 18 July 2019

Drug Discovery News

  • Regenerative Therapy for heart failure enters Ph III Trial

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: Belgian biotechnology company Cardio3 BioSciences (C3BS) has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congest...Read more

  • Mesoblast to set up stem cell drug plant in Singapore

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 May, 2014

    Singapore: Australian regenerative drug company, Mesoblast, is planning to expand its global manufacturing base and the company is in dialogues with Singapore Economic Development Board (ED...Read more

  • Sanford-Burnham, Daiichi form new alliance

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 26 May, 2014

    Singapore: US based Sanford-Burnham Medical Research Institute and Japan's Daiichi Sankyo have formed a three year discovery and pre-clinical drug development partnership for cardiovascular...Read more

  • Boehringer, Eli Lilly to evaluate Trajenta for type 2 diabetes

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Boehringer Ingelheim and Eli Lilly have initiated phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albumin...Read more

  • Taiwan firm NCE to get priority review in China

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Mar, 2013

    Singapore: Taiwan Liposome Company's multi-mechanistic anti-cancer new chemical entity Lipotecan has been accepted into the "Green Path" program by the Chinese State Food and Drug Administr...Read more

  • Astrazeneca, China university in research deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 19 Dec, 2012

    Singapore: AstraZeneca has signed a research collaboration with Fudan University, one of China's leading academic institutions in the area of cardiovascular diseases (CVDs). CVDs are a lead...Read more

  • Phylogica extends collaboration with Janssen Biotech

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 31 Jan, 2013

    Singapore: Phylogica, a leading Australian peptide drug discovery company, has extended its collaboration with Janssen Biotech and its affiliates to discover, develop and commercialize new ...Read more

  • AstraZeneca, BMS gets positive regulatory feedback on Type 2 diabetes drug

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 29 Nov, 2013

    Singapore: Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided AstraZeneca and Bristol-Myers Squibb a positive opinion recommending app...Read more

  • Regeneron acquires Sanofi eye care antibodies

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 06 May, 2013

    Singapore: US-based Regeneron Pharmaceuticals has acquired exclusive rights to two families of novel antibodies from Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF ...Read more

  • Teva, Xenon enter $335 mn deal for pain drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Dec, 2012

    Singapore: Israel-based Teva Pharmaceutical and Canada-based Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is curre...Read more

  • Linaclotide phase III trial initiated in China

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Sep, 2013

    Singapore: Ironwood Pharmaceuticals and AstraZeneca Pharmaceuticals have announced the initiation of a phase III clinical trial of linaclotide in China for the treatment of adults with irri...Read more

  • Singapore firm, Stehlin Foundation collaborate on anti-cancer drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 15 Oct, 2013

    Singapore: NanoMaterials Technology (NMT), a Singapore based company, has signed an exclusive material supply agreement with Houston-based CHRISTUS Stehlin Foundation for Cancer Research (S...Read more

  • AseaCyte gets BioSpectrum award for drug discovery efforts

    Drug Discovery |  Influencers | By BioSpectrum Bureau  | 0 Comment | 15 Mar, 2013

    A meeting between Dr Teo Soo Hwang, current CEO of AseaCyte; Dr Lee Hong Boon from Cancer Research Initiatives Foundation (CARIF), a non-profit cancer research institute in Malaysia; and Dr...Read more

  • Abraxane cancer trial shows positive results in Australia

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 Oct, 2012

    Singapore: Specialised Therapeutics Australia (STA) is going to publish abstracts related to its phase III metastatic melanoma study with Abraxane (nanoparticle albumin-bound paclitaxel) at...Read more

  • Astellas, Ambit terminate cancer drug deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 12 Mar, 2013

    Singapore: Japan-based Astellas Pharma and US-headquartered Ambit Biosciences are ending their collaboration for joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3)...Read more

  • Roche launches FLOW system

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 18 Dec, 2013

    Singapore: Roche has launched FLOW system, a user defined system for workflow chain from primary sample handling to qPCR result analysis, for use in laboratory developed tests (LDT) in Euro...Read more

  • TB prevention faces gap of $1.6bn: WHO estimates

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: WHO and Global Fund to Fight AIDS, TB and Malaria have stressed on strains of tuberculosis with resistance to multiple drugs could spread widely and highlighted an annual need of...Read more

  • Edison Pharma, DSP enter $4 bn metablosim drug deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 04 Feb, 2014

    Singapore: US-based Edison Pharmaceuticals has entered into a strategic alliance valued up to $4.295 billion with Japan's Dainippon Sumitomo Pharma (DSP) for the development of drugs target...Read more



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls